The memory - eating
disease, expected to afflict 15 million Americans by 2060 (and tens of millions more around the world as life expectancy increases), has no
cure; a new drug
for the condition hasn't been approved in well over a decade; initially promising experimental treatments seem to be failing with clockwork regularity; and there's not even a
definitive consensus on what, exactly, biopharma companies should focus on while developing Alzheimer's medicines.